Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1510829-06-7
2. Biib-062
3. Bsk-4841
4. Fp0182
5. Vecabrutinib [inn]
6. Vecabrutinib [usan]
7. Pq7o0ob5gu
8. Fp-0182
9. Sns062
10. (3r,3'r,4's)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-[3-chloro-5-(trifluoromethyl)anilino]-2-oxo[1,3'-bipiperidine]-4'-carboxamide
11. (3r,3'r,4's)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluoromethyl)phenyl)amino)-2-oxo-(1,3'-bipiperidine)-4'-carboxamide
12. (3r,3'r,4's)-1'-(6-amino-5-fluoropyrimidin-4-yl)-3-((3-chloro-5-(trifluoromethyl)phenyl)amino)-2-oxo-[1,3'-bipiperidine]-4'-carboxamide
13. Unii-pq7o0ob5gu
14. Vecabrutinib (usan/inn)
15. Vecabrutinib [usan:inn]
16. Biib062
17. Vecabrutinib [who-dd]
18. Chembl4297640
19. Schembl16765727
20. Gtpl10231
21. Bcp29646
22. Ex-a3159
23. Bdbm50546200
24. Fp-182
25. Nsc810114
26. Who 10643
27. Zb1596
28. Nsc-810114
29. Ac-36339
30. Hy-109078
31. Cs-0033553
32. D11428
33. (1,3'-bipiperidine)-4'-carboxamide, 1'-(6-amino-5-fluoro-4-pyrimidinyl)-3-((3-chloro-5-(trifluoromethyl)phenyl)amino)-2-oxo-, (3r,3'r,4's)-
34. (3r,4s)-1-(6-amino-5-fluoropyrimidin-4-yl)-3-[(3r)-3-[3-chloro-5-(trifluoromethyl)anilino]-2-oxopiperidin-1-yl]piperidine-4-carboxamide
| Molecular Weight | 529.9 g/mol |
|---|---|
| Molecular Formula | C22H24ClF4N7O2 |
| XLogP3 | 2.7 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 5 |
| Exact Mass | 529.1616134 g/mol |
| Monoisotopic Mass | 529.1616134 g/mol |
| Topological Polar Surface Area | 131 Ų |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 809 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 3 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
ABOUT THIS PAGE
A Vecabrutinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Vecabrutinib, including repackagers and relabelers. The FDA regulates Vecabrutinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Vecabrutinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Vecabrutinib supplier is an individual or a company that provides Vecabrutinib active pharmaceutical ingredient (API) or Vecabrutinib finished formulations upon request. The Vecabrutinib suppliers may include Vecabrutinib API manufacturers, exporters, distributors and traders.
Vecabrutinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Vecabrutinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Vecabrutinib GMP manufacturer or Vecabrutinib GMP API supplier for your needs.
A Vecabrutinib CoA (Certificate of Analysis) is a formal document that attests to Vecabrutinib's compliance with Vecabrutinib specifications and serves as a tool for batch-level quality control.
Vecabrutinib CoA mostly includes findings from lab analyses of a specific batch. For each Vecabrutinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Vecabrutinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Vecabrutinib EP), Vecabrutinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Vecabrutinib USP).
LOOKING FOR A SUPPLIER?
